Medical device company Vitrolife AB (STO:VITR) on Friday reported net income of SEK71m, or EPS of SEK3.28, for the second quarter of 2017, from April 2017 to June 2017.
This was in comparison with net income of SEK48m, or EPS of SEK2.21, in Q2 of 2016.
Sales for the quarter amounted to SEK285m, up by 37% as compared with SEK208m in Q2 2016. Net sales growth was 33% in local currency.
Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.
(EUR1.00=SEK9.54)
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government